As foreseen in our last update, the future location of the European Medicines Agency (EMA) has now been announced. We understand that the new location of Amsterdam, in the Netherlands, promises one of the best options for retention of EMA personnel which in turn will promote continuity of operations. This prospective, post-Brexit location for the EMA which is only about 350 km (220 miles) from its current home in London, retains excellent transport links for the agency and offers another strong, national competent authority for local co-operation with the EMA in events, where appropriate. PharmaLex welcomes the news and clarity that this development brings with respect to planning for regulators and industry alike. Keep watching this site as we will continue our reporting on what the UK’s prospective withdrawal from the EU means for the regulation of pharmaceuticals and our customers. Over 2,600 final products have some stage of manufacture within in the UK.
If you would like to discuss your requirements in relation to Brexit-planning, please contact us on email@example.com.